Non-profit hospice organizations operate under a financial model that for-profit competitors do not face: every dollar spent on operations is a dollar that cannot go toward mission. Boards, donors, and community stakeholders expect operational efficiency precisely because resources are finite and the organization exists to serve — not to generate returns.
Pharmacy is one of the largest controllable costs in a hospice’s operating budget. Under the Medicare Hospice Benefit, drug costs are absorbed into the per diem rate. There is no separate pharmaceutical reimbursement. What your organization pays for medications is what it costs — and the difference between optimized and unoptimized pharmacy spend can reach six figures annually for a mid-sized non-profit hospice program.
For non-profit hospice leaders, pharmacy benefit management is not a procurement exercise. It is a financial stewardship decision.
The Non-Profit Financial Reality
Non-profit hospices face a specific version of the cost management challenge. Their revenue model is the same as for-profit hospices — Medicare per diem rates, with some variation for Medicaid and private insurance — but their margin tolerance is different. A for-profit organization can absorb pharmacy inefficiency and attribute it to competitive positioning or growth costs. A non-profit organization accountable to a board and a donor community has less flexibility.
The per-patient-per-day (PPD) benchmark is where this pressure becomes concrete. Industry average PPD runs between $8 and $12. Hospices with optimized PBM arrangements and well-designed formularies routinely achieve PPD in the $5 to $6 range. MaxHaven’s average PPD is $5.44.
For a non-profit hospice serving 75 patients:
- At $10 PPD: annual pharmacy spend of approximately $273,750
- At $5.44 PPD: annual pharmacy spend of approximately $148,890
- Annual difference: more than $124,000
That $124,000 is the operational gap between a mediocre pharmacy arrangement and an optimized one. For a non-profit hospice, it represents staff positions, expanded bereavement programs, community outreach, or simply financial sustainability.
What Non-Profit Hospices Often Inherit
Many non-profit hospice programs — especially those affiliated with hospitals, health systems, or faith-based organizations — inherit their pharmacy arrangements rather than designing them. A hospital-affiliated hospice may have been placed into the health system’s retail pharmacy contract. A community-founded program may have built relationships with a local retail pharmacy before understanding what a hospice-specialized PBM could offer.
These inherited arrangements are typically not optimized for hospice:
Retail Pharmacy Pricing
Retail pharmacy pricing is designed for individual consumers, not for the concentrated formulary and high-volume prescribing patterns of a hospice program. Symptom management medications, pain management agents, and respiratory medications — the core of a hospice formulary — are priced differently in a structured PBM arrangement.
Absence of Formulary Management
The absence of formulary management allows prescribing patterns to drift over time. Without a formulary that reflects both clinical best practices and cost efficiency, high-cost outliers accumulate. PPD climbs without a clear explanation, and the organization lacks the benchmarking data to understand why.
No Transparency on Pricing Structure
In many inherited retail arrangements, the organization has no visibility into whether it is being charged retail, contracted, or acquisition pricing. For a non-profit board conducting financial oversight, this opacity is a problem.
What Board-Level Financial Oversight Requires
Non-profit hospice boards take their fiduciary responsibilities seriously. Program directors and CFOs who present pharmacy data to their boards need to be able to answer specific questions:
- What is our current PPD, and how does it compare to industry benchmarks?
- What is the structure of our PBM arrangement, and are we paying acquisition cost plus a transparent fee, or a less visible pricing structure?
- What controls are in place to manage high-cost drug claims before they affect the operating budget?
- Do we have the audit rights to verify what we are paying?
MaxHaven is designed to make these questions answerable. Our no-spread-pricing model means the organization pays the actual cost of drugs plus a clear administrative fee — nothing else. PPD is trackable from day one, benchmarkable against industry data, and reportable at the board level without qualification.
Formulary Governance for Non-Profit Programs
For non-profit organizations with clinical advisory boards or medical directors involved in program governance, formulary transparency is an additional requirement. The formulary is not just a cost control tool — it is a clinical document that reflects the organization’s values around patient care.
MaxHaven’s formulary was developed by palliative care pharmacists around the actual clinical requirements of the Medicare Hospice Benefit. It covers what hospice patients need. It manages high-cost outliers through structured prior authorization and formulary tier design. And it gives the organization’s clinical leadership a defensible, documented basis for prescribing decisions.
For a non-profit with a clinical governance structure, the ability to present the formulary as a purpose-built clinical and financial tool — not a retail pharmacy’s default product catalog — matters.
The Transition Conversation
Non-profit hospice leaders who recognize a gap between their current pharmacy arrangement and a better one often hesitate at the transition question: how disruptive is switching PBMs, and is the financial upside worth it?
MaxHaven’s answer is straightforward. We will do a no-cost PPD analysis using your current pharmacy data before any commitment is made. We will show you exactly what your current arrangement is costing, what an optimized MaxHaven arrangement would look like, and what the annual financial impact of that difference is.
If the math doesn’t justify the change, we will tell you that. Non-profit hospice organizations have too many demands on their attention to pursue transitions that don’t generate meaningful return.
If the math does justify it — and for most organizations paying retail or near-retail pharmacy pricing, it does — we will manage the transition in a way that minimizes clinical disruption and gets your PPD where it should be.
Managing pharmacy costs is part of the mission — not separate from it.
Request a Free PPD Analysis | Talk to a MaxHaven Specialist
MaxHaven RX is a hospice-specialized pharmacy benefit manager and part of the PPOK family of pharmacy brands. We serve hospice administrators, executive leaders, non-profit programs, hospital-based hospice programs, consortia, and new hospice organizations. Our average PPD: $5.44.
